Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Basilea Pharmaceutica

Tracked across 5 events · 32 articles · First seen May 27, 2026 · Last active Sep 16, 2026

Sentiment
29
Attention
4
Events
5
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 70
Business
Impact: Basilea Pharmaceutica received USD 13.3 million in funding from United States — Biomedical Advanced Research and Development Authority>>> to continue the development of its novel antibiotic, ceftibuten-ledaborbactam etzadroxil. This funding supports the advancement of its clinical phase 3 program, addressing a critical unmet need for oral treatment of complicated urinary tract infections.
May 27, 2026 · 7 articles
2 60
Business
Impact: Basilea received $30M milestone payment from BARDA, advancing its Phase 3 fosmanogepix program; stock rose 2.32%.
Jul 29, 2026 · 6 articles
1 15
Tech
Basilea Pharmaceutica announced that its Japanese partner Asahi Kasei started a Phase 2 clinical study of the antifungal Cresemba (isavuconazole) in Japan for pediatric patients at risk of deep mycoses. The multicenter, open-label, non-controlled study…
Impact: Basilea is the originator of Cresemba and the main beneficiary of the pediatric study start in Japan, which could broaden the drug's label and future sales. The company also highlighted its broader anti-infective pipeline and a solid cash position of CHF 175.98 million.
Sep 14, 2026 · 6 articles
2 0
Business
Impact: Basilea Pharmaceutica is the licensor of ZEVTERA to Innoviva.
Jun 01, 2026 · 6 articles
0 0
Business
Alkermes (Nasdaq: ALKS) announced the appointment of Anne C. Whitaker as a new independent director to its Board of Directors. The appointment was announced on Wednesday, September 16, 2026, according to a company press release.…
Impact: Basilea is a company where Whitaker currently serves on the board, mentioned as background.
Sep 16, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Basilea Pharmaceutica live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.